Axitinib(AG 013736)
1 Inquiries
319460-85-0
2026-09-28
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Product Description
-
Seller Information
-
Inquiry History
-
Description
ProductName Axitinib(AG 013736) Cat No CEI-0889 Description Axitinib (AG-013736) is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM, respectively. Alias AG 013736 CAS No 319460-85-0 Molecular Weight 386.47 Storage 2 years -20 centigrade Powder; 2 weeks 4 centigrade in DMSO; 6 months -80 centigrade in DMSO. Synonyms AG 013736 Targets VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit IC50 0.1 nM;0.2 nM; 0.1-0.3 nM; 1.6 nM; 1.7 nM Molecular Formula C22H18N4OS Solubility DMSO 42 mg/mL; Water <1 mg/mL; Ethanol <1 mg/mL In vitro Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts.Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg.Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma. category Antineoplastic Agents(c1417) cas_num 319460-85-0 ECHEMI Editorial ReferenceAxitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively.
Axitinib is an indazole substituted at position 3 by a 2-(pyridin-2-yl)vinyl group and at position 6 by a 2-(N-methylaminocarboxy)phenylsulfanyl group. Used for the treatment of advanced renal cell carcinoma after failure of a first line systemic treatment. It has a role as an antineoplastic agent, a tyrosine kinase inhibitor and a vascular endothelial growth factor receptor antagonist. It is a member of indazoles, a member of pyridines, an aryl sulfide and a member of benzamides.|Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors. Axitinib is an indazole derivative. It is most commonly marketed under the name Inlyta® and is available in oral formulations.|Axitinib is a Kinase Inhibitor. The mechanism of action of axitinib is as a Receptor Tyrosine Kinase Inhibitor.|Axitinib is an oral tyrosine kinase inhibitor selective for vascular endothelial growth factor (VEGF) receptors -1, -2 and -3 that is used in the therapy of advanced renal cell carcinoma. Axitinib therapy is commonly associated with transient elevations in serum aminotransferase that are generally mild and asymptomatic. Axitinib has yet to be linked to instances of clinically apparent acute liver injury.|Axitinib is an orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect.|A benzamide and indazole derivative that acts as a TYROSINE KINASE inhibitor of the VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR. It is used in the treatment of advanced RENAL CELL CARCINOMA.Basic Info-
Product Name:
Axitinib
Other Name:Benzamide,N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-;N-Methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]benzamide;AG 013736;Axitinib;Inlyta;790713-39-2
CAS No.:319460-85-0
Molecular Formula:C22H18N4OS
InChIKeys:InChIKey=RITAVMQDGBJQJZ-FMIVXFBMSA-N
Molecular Weight:386.47
Exact Mass:386.47
EC Number:1308068-626-2
UNII:C9LVQ0YUXG
NSC Number:757441
DSSTox ID:DTXSID3049049
NCI Thesaurus Code:C38718
ATC Code:L01EK01|L01XE17|L - Antineoplastic and immunomodulating agents
HScode:2933990090
Categories:
Characteristics-
PSA:
96
XLogP3:4.2
Appearance:white to tan
Density:1.4±0.1 g/cm3
Melting Point:213-215°C
Boiling Point:668.9°C at 760 mmHg
Flash Point:358.3±31.5 °C
Refractive Index:1.728
Water Solubility:In aqueous media with a pH between 1.1 to 7.8, axitinib has a solubility of over 0.2 μg/mL.DMSO: ≥8mg/mL
Storage Conditions:-20°C Freezer
Dissociation Constants:4.8
Hazard IdentificationClassification of the substance or mixture
Acute toxicity - Category 4, Oral
Hazardous to the aquatic environment, short-term (Acute) - Category Acute 1
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Warning
Hazard statement(s) H302 Harmful if swallowed
H400 Very toxic to aquatic life
Precautionary statement(s) Prevention P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P273 Avoid release to the environment.
Response P301+P317 IF SWALLOWED: Get medical help.
P330 Rinse mouth.
P391 Collect spillage.
Storage none
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Location:
Shirley, New York 11967, USA
-
Payment Terms:
TT against copy of documents,D/P
-
Average lead Time:
15
-
Total Annual Revenue:
$1 million-$2.5 million
-
Year of Establishment:
2004
-
-
Inquiry History1 Inquiries
Country Product Purchase Quantity Date Posted 
India
AXITINIB
1 KG Oct 27, 2025 Post an enquiry for this product